Menu

Experience

Susan Cooper Philpot

    • Uber Closes SoftBank Investment 


    • Personal Shopping Service Stitch Fix Raises $120 Million in IPO 


    • Cooley Advised Jazz Pharmaceuticals on Rule 144A Offering of $575 Million of Exchangeable Senior Notes 


    • Aridis – $26 Million IPO 


    • Medivation Agrees to Sell to Pfizer for $14 Billion 


    • Uber to Buy Self-Driving Truck Startup Otto 


    • Advaxis – $30 Million Registered Direct Offering 


    • Gemphire Therapeutics – $30 Million IPO 


    • Syros – $58 Million IPO 


    • Syros IPO – $58 Million 


    • Inotek Pharmaceuticals – $50 Million Follow-On 


    • Syndax – $58 Million IPO 


    • AveXis – $95 Million IPO 


    • Atlassian - $531 Million IPO 


    • Voyager Therapeutics - $80.5 Million IPO 


    • Strongbridge Biopharma IPO 


    • NantKwest IPO - $238 Million IPO 


    • ProNAi Therapeutics - $158 Million IPO 


    • Ooma Prices $65 Million IPO 


    • NantKwest – $238 Million IPO 


    • Catabasis Completes $69 Million IPO 


    • ProNAi – $158 Million IPO 


    • NVIDIA Secures $380 Million Synthetic Lease for New Headquarters 


    • MINDBODY Completes $100 Million IPO 


    • MINDBODY Completes $100 Million IPO 


    • HTG Completes its Initial Public Offering 


    • Apigee Completes Initial Public Offering 


    • Jawbone Acquisition of Body Media 


    • KemPharm Completes its IPO 


    • Cidara Completes Initial Public Offering  


    • Horizon Pharma Completes $400 Million Exchangeable Senior Notes Offering 


    • Rovi Corporation Completes $345 Million Convertible Note Offering 


    • Invitae Completes $117 Million Initial Public Offering  


    • Ascendis Pharma closes $124 million IPO 


    • Bellicum Pharmaceuticals $160 million IPO 


    • TRACON Pharmaceuticals Completes Initial Public Offering 


    • New Relic Completes $132 Million Initial Public Offering 


    • New Relic Completes $132 Million Initial Public Offering  


    • Ionis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes 


    • Ionis Pharmaceuticals Completes Rule 144A Offering $500 Million of Convertible Senior Notes 


    • Xenon Pharmaceuticals Completes Initial Public Offering 


    • Atara – $63 Million IPO and Follow-On Offerings 


    • Vascular Biogenics Prices IPO 


    • Demira Prices $125 Million IPO 


    • T2 Biosystems IPO 


    • Jazz Pharmaceuticals plc Rule 144A Offering of $575 Million of Exchangeable Senior Notes 


    • Otonomy $100 Million IPO 


    • Immune Design $63 Million Initial Public Offering 


    • HealthEquity $146 Million Initial Public Offering 


    • Jazz Pharmaceuticals – $575 Million Exchangeable Senior Note Offering 


    • Minerva Neurosciences $32.7 Million IPO 


    • Kite Pharma $146 Million Initial Public Offering 


    • Zendesk's $115 Million Initial Public Offering 


    • Alder Biopharmaceuticals $80 Million Initial Public Offering 


    • TriVascular Initial Public Offering 


    • Vital Therapies Initial Public Offering 


    • Cooley Advises Underwriters on Vital Therapies IPO 


    • Aerohive Networks $75 Million IPO 


    • TriNet – $276 million IPO and $352 million follow-on 


    • Castlight Health's $204 Million IPO 


    • Amedica Initial Public Offering 


    • Auspex $96 Million Initial Public Offering 


    • Egalet Corporation IPO 


    • Eleven Biotherapeutics IPO 


    • Trevena $64 Million Initial Public Offering 


    • Cooley Advises Auspex on its Initial Public Offering 


    • First US IPO of 2014 for GlycoMimetics 


    • Five Prime Therapeutics IPO 


    • LinkedIn's $1.25 Billion Follow-On Offering 


    • Onconova Therapeutics IPO 


    • Epizyme, Inc. Initial Public Offering 


    • Portola Pharmaceuticals $140 Million IPO 


    • Ambit Initial Public Offering 


    • Cyan, Inc. Initial Public Offering 


    • Receptos, Inc. Initial Public Offering 


    • Cooley Advises Ambit on its IPO 


    • Insys Therapeutics IPO 


    • Jawbone Acquisition of Body Media 


    • Minerva – $58 Million Follow-On Offering 


    • Redfin – $159 Million IPO 


Contact us

Back to top

© 2019 Cooley LLP and Cooley (UK) LLP. All rights reserved.

Cooley® is a registered service mark of Cooley LLP in the United States and European Union as well as certain other jurisdictions.